Menu
The World Federation of Hemophilia (WFH) publishes internationally recognized guidelines to support the care and treatment of people with inherited bleeding disorders.
These guidelines were published in 2021 as a collaboration between The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) and are intended to support patients, clinicians, and other health care professionals in their decisions about VWD diagnosis and management.
The two guidelines are:
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
Glenn Pierce, MD, PhD
WFH Vice President, Medical
The World Federation of Hemophilia has published the third edition of Guidelines for the Management of Hemophilia. Developed through a formal evidence-informed and consensus-based methodology involving multidisciplinary healthcare professionals (HCPs) and well-informed people with hemophilia (PWH), these guidelines offer 340 practical recommendations on managing care for PWH. The guidance provides a framework for the development of a comprehensive healthcare system supporting PWH, including advocacy and patient empowerment.
These materials are derived from the WFH Guidelines for the Management of Hemophilia, 3rd edition [© 2020 World Federation of Hemophilia. Haemophilia © 2020 John Wiley & Sons Ltd]
For the full set of recommendations, please refer to the full WFH Treatment Guidelines, available here.
For questions, contact treatmentguidelines@wfh.org
These educational materials were made possible through the support of the Hemophilia Alliance.
Narrated video